Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Vitamin K vs control PIVKA II levels: change in PIVKA II (ng/mL) · people with cystic fibrosis Vitamin K supplementation for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Vitamin K vs control Uncarboxylated osteocalcin: change in carboxylation of osteocalcin (% Glu‐OC) · people with cystic fibrosis Vitamin K supplementation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Time to cessation of bleeding · people with cystic fibrosis Vitamin K supplementation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Bone mineral density: lumbar spine z score · people with cystic fibrosis Vitamin K supplementation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 324 participants | Low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Lung function: FVC mL or % predicted (change from baseline) · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1261 participants | Low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Lung function: FEF25-75 mL/s or % predicted (change from baseline) · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1261 participants | Low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 123 participants | Low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) HRQoL ‐ change from baseline in CFCS total score and CFQ‐R respiratory domain · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Lung function: FEV1 mL% predicted (change from baseline) · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Lung function: FEV1 % predicted (change from baseline) · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Lung function: FVC % predicted (change from baseline) · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Lung function: FEF25-75 % predicted (change from baseline) · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Adverse events relating to treatment · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Low |
Summary of findings ‐ Inhaled mannitol vs dornase alfa HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 231 participants | Very low |
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 600 participants | Moderate |
Summary of findings ‐ Inhaled mannitol vs dornase alfa Lung function: FEV1 mL (percentage change from baseline) · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | MD 2.8 | 231 participants | Very low |
Summary of findings ‐ Inhaled mannitol vs dornase alfa Lung function: FEV1 % predicted · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Inhaled mannitol vs dornase alfa Lung function: FVC mL (percentage change from baseline) · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | MD 0.14 | 231 participants | Very low |
Summary of findings ‐ Inhaled mannitol vs dornase alfa Lung function: FEF25-75 mL/s (percentage change from baseline) · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 231 participants | Very low |
Summary of findings ‐ Inhaled mannitol vs dornase alfa Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 231 participants | Very low |
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young people with cystic fibrosis Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 231 participants | Very low |
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa Lung function: FEV1mL (percentage change from baseline) · children and young people with cystic fibrosis Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 231 participants | Very low |
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa Lung function: FEV1 % predicted · children and young people with cystic fibrosis Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa Lung function: FVC mL (percentage change from baseline) · children and young people with cystic fibrosis Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 231 participants | Very low |
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa Lung function: FEF25-75 mL/s (percentage change from baseline) · children and young people with cystic fibrosis Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 231 participants | Very low |
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol Lung function: FEV1 % predicted (change from baseline) · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 600 participants | Moderate |
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young people with cystic fibrosis Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 231 participants | Very low |
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol Lung function: FVC mL (change from baseline) · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 600 participants | Moderate |
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol Lung function: FEF25-75 mL/s (change from baseline) · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 600 participants | Moderate |
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 600 participants | Moderate |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 391 participants | Very low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Lung function: FEV1 mL (absolute change from baseline) · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 391 participants | Low |
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol) Lung function: FEV1 % predicted (change from baseline) · adults, children and young people with CF Inhaled mannitol for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1261 participants | Low |
Inhalation before vs during airway clearance techniques FEV1 % predicted · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | 2 studies · 63 participants | Low |
Inhalation before vs after airway clearance techniques QoL · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Inhalation before vs after airway clearance techniques Symptom scores · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Inhalation before vs after airway clearance techniques Measures of sputum clearance · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Inhalation before vs after airway clearance techniques LCI · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Inhalation before vs after airway clearance techniques Adverse events · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Inhalation during vs after airway clearance techniques FEV1 % predicted · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Inhalation during vs after airway clearance techniques FVC % predicted · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Inhalation during vs after airway clearance techniques QoL · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Inhalation during vs after airway clearance techniques Symptom scores · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Inhalation during vs after airway clearance techniques Measures of sputum clearance · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Inhalation before vs during airway clearance techniques FVC % predicted · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Inhalation during vs after airway clearance techniques LCI · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Inhalation during vs after airway clearance techniques Adverse events · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Inhalation before vs during airway clearance techniques QoL · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Inhalation before vs during airway clearance techniques Symptom scores · adults and children with cystic fibrosis Timing of hypertonic saline inhalation for cystic fibrosis (2020) · Cochrane | no estimate extracted | 3 studies · 76 participants | Low |